COLLABORATION

Boehringer Ingelheim and 3T Biosciences Collaborate to Develop Next-Generation Cancer Immunotherapies

Read

Boehringer Ingelheim and 3T Biosciences recently announced a strategic collaboration to address unmet patient needs.

3T Biosciences is combining with Boehringer Ingelheim's best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform to significantly enhance the pipeline. The 3T platform intends to find novel common T-cell receptor (TCR) targets for effective immune responses and screen them thoroughly for specificity and cross-reactivities.

The aim is to discover the most frequent and immunogenic targets in solid tumours by combining highdiversity target libraries with active machine learning. The end result would be more targeted, high-dose medicines that can safely attack specific tumours.

Boehringer Ingelheim will contribute patient-derived TCR data to support 3T's target discovery activities using its 3T TRACE discovery platform.

Boehringer will pay 3T a total of US$268 million, including an upfront payment & ongoing research and development assistance.

Boehringer Ingelheim is qualified to collect royalties on product sales made by 3T Biosciences.